European Radiology

, Volume 22, Issue 7, pp 1573–1578 | Cite as

Cystic versus predominantly cystic thyroid nodules: efficacy of ethanol ablation and analysis of related factors

  • Young Joong Kim
  • Jung Hwan Baek
  • Eun Ju Ha
  • Hyun Kyung Lim
  • Jeong Hyun Lee
  • Jin Young Sung
  • Jae Kyun Kim
  • Tae Yong Kim
  • Won Bae Kim
  • Young Kee Shong
Head and Neck

Abstract

Objectives

To compare the efficacy of ethanol ablation (EA) of cystic and predominantly cystic thyroid nodules, and to evaluate factors affecting efficacy.

Methods

From October 2008 to December 2010, a total of 217 thyroid nodules were treated with EA. Nodule volumes, symptoms and cosmetic scores were evaluated before and after EA. EA efficacy in treating cystic and predominantly cystic nodules was compared; and factors related to EA efficacy in each type, including initial volume, solid component, vascularity, fluid nature, ethanol retention time and number of EA sessions, were evaluated.

Results

Mean nodule volume decreased from 15.7 ± 18.1 ml to 3.0 ± 7.9 ml (mean volume reduction, 85.2 ± 16.1%) and the therapeutic success rate was 90.3% at last follow-up. EA was significantly more effective in cystic than predominantly cystic nodules. Independent predictors of EA efficacy for all nodules included initial volume, solid component and vascularity. Initial volume and vascularity were independent predictors of EA efficacy in predominantly cystic nodules, but no factor was independently related to efficacy in cystic nodules.

Conclusions

EA is effective in both cystic and predominantly cystic nodules, especially the former. EA is less effective in large or vascular predominantly cystic nodules, but is effective in cystic nodules regardless of related factors.

Key Points

Ethanol ablation under ultrasound guidance is increasingly used for cystic thyroid nodules.

EA seems effective for cystic and predominantly cystic nodules, especially cystic nodules.

The effectiveness of EA was reduced in large or vascular predominantly cystic nodules.

Keywords

Ethanol ablation Radiofrequency ablation Thyroid cyst Thyroid nodule Thyroid intervention 

Introduction

Benign thyroid nodules are not uncommon, with ultrasound examination showing that 15–25% of solitary thyroid nodules are cystic or predominantly cystic [1, 2, 3]. Simple aspiration of the cystic portion is the initial treatment of choice, both for diagnosis and for reducing cyst volume. Collapse of thyroid cysts after simple aspiration have been reported; however, recurrence rates are as high as 80%, depending on the initial volume and internal contents of the nodule, and the number of aspirations [1, 4, 5, 6, 7]. For recurrent cases after aspiration, ethanol ablation (EA) has been attempted and achieved good results [2, 8, 9, 10].

Despite the effectiveness of EA in treating cystic and predominantly cystic thyroid nodules, about 5–25% of patients have nodules refractory to EA [1, 2, 8, 11]. The efficacy of repeat EA of refractory nodules is considerably reduced [1] and may be dependent on the percentage of solid component, the initial volume of the nodule and the amount of injected ethanol [2, 6, 7, 12]. The percentage of solid component has been shown to be the most important factor [13, 14]. Volume reduction after EA has been reported to be greater for cystic than for solid nodules (64% versus 35%), suggesting that solid components are more resistant to the diffusion of ethanol and that the vascularity of the solid component favours the drainage of ethanol, thus limiting the success of the procedure [7]. Despite these findings, no study to date has evaluated the importance of the solid component by comparing the effects of EA on cystic and predominantly cystic thyroid nodules. We therefore tested the hypothesis that the efficacy of EA in cystic thyroid nodules is dependent on the percentage of solid component. To test this hypothesis, we retrospectively evaluated the efficacy of EA in a large series of cystic and predominantly cystic thyroid nodules. We also evaluated various factors related to the efficacy of EA.

Materials and methods

Patient enrolment

The protocol of this retrospective study was approved by our Institutional Review Board, which did not require patient approval or informed consent for review of images and medical records. However, all patients undergoing ultrasound-guided fine-needle aspiration (FNA) and EA provided written informed consent before each procedure.

From October 2008 to December 2010, a total of 217 cystic and predominantly cystic thyroid nodules in 209 patients were treated with EA at Asan Medical Center and Daerim Saint Mary’s Hospital. The patient population consisted of 48 male and 161 female patients, aged 8–80 years (mean age, 47.7 years). All enrolled patients had:
  1. 1.

    Nodules with a cystic portion greater than 50%

     
  2. 2.

    Pressure symptoms or cosmetic problems

     
  3. 3.

    Serum thyroid hormone and thyrotropin concentrations within normal limits

     
  4. 4.

    Cytologically confirmed benign nodules after two separate ultrasound-guided FNAs

     
  5. 5.

    No malignant features on ultrasound examination [15, 16, 17]

     

Pre-ablation assessment

All patients underwent ultrasound and ultrasound-guided FNA examinations, performed by one of three radiologists (J.H.B., J.H.L. and J.Y.S.) all with 11–13 years experience in these techniques, using a 5- to 14-MHz linear probe fitted to a real-time ultrasound system (EUB-7500, Hitachi; iU-22, Philips; Aplio SSA-770A, Toshiba). Nodule size, proportion of solid component, vascularity and internal fluid composition were assessed on ultrasound and ultrasound-guided FNA. The three orthogonal diameters of each nodule (the largest diameter and two diameters perpendicular to it) were measured, and the volume of each nodule was calculated as: V = πabc/6 (where V is volume, a is the largest diameter, and b and c are the other two perpendicular diameters) [18, 19]. Nodules with <10% solid component were classified as cystic, whereas those with 10–50% solid component were classified as predominantly cystic. Vascularity was graded into four categories (grade 0, no intranodular vascularity; grade 1, perinodular vascularity only; grade 2, intranodular vascularity <50%; grade 3, intranodular vascularity >50%). Internal fluid composition was classified as colloid or non-colloid.

At enrolment, patients were asked to rate their symptom score on a 10-cm visual analogue scale (0–10). Physicians recorded a cosmetic grade (1, no palpable mass; 2, a palpable mass but no cosmetic problem; 3, cosmetic problem on swallowing only; 4, readily detected cosmetic problem) [20, 21, 22, 23].

Procedure

All procedures were performed on an outpatient basis. None of the patients received intravenous sedatives or analgesics before or during the procedure. Patients were placed in a supine position with mild neck extension. After skin sterilisation and anaesthesia with 2% lidocaine at the puncture site, a 14– to 18-gauge needle was inserted into the nodule under ultrasound guidance via the trans-isthmic approach, thus preventing a change in the position of the needle tip and of ethanol leakage while swallowing [13, 14, 17, 18, 21, 22, 23, 24, 25]. The maximum volume of internal fluid was aspirated, residual debris or colloid was removed by saline irrigation [20], and 99% ethanol was injected slowly into the cystic space. The volume of injected ethanol usually corresponded to about 50% of the volume of aspirated fluid. Ethanol retention times for EAs performed by J.H.B., J.H.L. and J.Y.S. were 2, 5 and 10 min, respectively, the times used by each radiologist in clinical practice. The ethanol was removed completely, and the needle was withdrawn slowly with minimal negative pressure of the syringe, thus preventing ethanol leakage outside the thyroid gland. During and immediately after EA, any discomfort or complications associated with the procedure were evaluated. Procedure-related pain was graded into four categories (grade 0, no pain or mild pain similar to pain during lidocaine injection; grade 1, pain greater than lidocaine injection, but not needing medication; grade 2, pain needing medication; grade 3, EA procedure incompletely terminated due to severe pain). Patients stayed in the hospital for 30 min after the procedure.

Repeat EA or radiofrequency (RF) ablation was performed on patients with (1) incompletely resolved symptoms (symptom score reduction <50%) or cosmetic problems, and/or (2) nodules showing a residual solid portion with internal vascularity on follow-up ultrasound examination [13, 14, 18]. Before retreatment of each patient, we explained the advantages and disadvantages of repeat EA or RFA, based on previous results [13, 14, 22], allowing all patients to choose a preferred treatment.

Follow-up

Follow-up ultrasound and clinical examinations were identical to those performed before EA. Ultrasound examinations were performed 1, 3, 6 and 12 months or later after the initial procedure. We carefully evaluated the position and nature of the treated nodule. Post-EA nodules tend to show marked hypoechogenicity with reduction in volume [26]. Thus, we could confirm that the nodule had undergone EA. Any complications during follow-up were evaluated.

Statistical analysis

All statistical analyses were performed using SPSS for Windows (version 18.0; SPSS, Chicago, IL, USA). Paired t-tests were used to compare changes in nodule volume, symptom score and cosmetic score from before EA to 1 month and last follow-up after EA. Student’s t-tests were used to compare volume reduction rate (VRR), and Pearson’s chi-squared test was used to compare rates of therapeutic success (volume reduction >50%) and need for additional treatment, of cystic and predominantly cystic thyroid nodules.

The relationships between VRR at last follow-up and various factors (initial volume, proportion of solid component, vascularity, internal fluid nature, ethanol retention time and number of sessions) were evaluated by bivariate correlation analysis. Multiple linear regression analysis was used to determine independent predictors of VRR, including initial volume (<10 ml versus >10 ml), proportion of solid component (cystic versus predominantly cystic), vascularity (grade 0 versus grades 1–3), nature of internal fluid (colloid versus non-colloid), ethanol retention time (<10 min versus 10 min), and number of sessions. One-way ANOVA was used to compare VRRs according to ethanol retention time (2 min versus 5 min versus 10 min). The significance level for all tests was defined as P < 0.05.

Results

We performed ethanol ablation in 217 thyroid nodules (127 cystic and 90 predominantly cystic nodules). The mean volume was 15.7 ± 18.1 ml. The vascularity of the nodules was: grade 0, 88 nodules; grade 1, 119 nodules; grade 2, nine nodules; grade 3, one nodule. Internal contents were colloid in 36 nodules and non-colloid in 181. Twenty-nine nodules required additional treatment, including 15 that underwent repeat EA (two sessions each for 14 nodules and three sessions for 1 nodule) and 14 that were treated by RF ablation. The mean follow-up period was 6.0 ± 5.6 months (range, 1–25 months).

The efficacy of EA is summarised in Table 1. The nodule volume decreased significantly, from 15.7 ± 18.1 ml (range, 1.1–112.3 ml) to 4.5 ± 8.7 ml (range, 0–91.4 ml) at 1 month (P < 0.001) and to 3.0 ± 7.9 ml (range, 0–91.4 ml) at last follow-up (P < 0.001). Mean VRR was 74.7 ± 19.7% after 1 month and 85.2 ± 16.1% at last follow-up. Mean symptom score and cosmetic grade also significantly improved at last follow-up (P < 0.001 each).
Table 1

Efficacy of ethanol ablation in total thyroid nodules and subgroups

Thyroid nodules

Initial

Last follow-up

P value

Total (n = 217)

 Volume (ml)

15.7 ± 18.1

3.0 ± 7.9

<0.001

 Symptom score

2.9 ± 2.6

0.6 ± 1.0

<0.001

 Cosmetic grade

3.7 ± 0.6

1.7 ± 0.9

<0.001

 Therapeutic success (%)

 

90.3

 

Cystic (n = 127)

 Volume (ml)

14.8 ± 16.4

1.8 ± 4.6

< 0.001

 Symptom score

2.6 ± 2.6

0.5 ± 1.0

<0.001

 Cosmetic grade

3.7 ± 0.6

1.5 ± 0.7

<0.001

 Therapeutic success (%)

 

96.1

 

Predominantly cystic (n = 90)

 Volume (ml)

16.6 ± 20.1

4.7 ± 10.9

<0.001

 Symptom score

3.3 ± 2.4

1.0 ± 1.3

<0.001

 Cosmetic grade

3.8 ± 0.6

2.0 ± 1.0

<0.001

 Therapeutic success (%)

 

82.2

 

Values are mean ± SD

Subgroup analysis showed that, although the mean initial volume of cystic and predominantly cystic nodules did not differ significantly (14.8 ± 16.4 ml versus 16.6 ± 20.1 ml, P = 0.348), the mean VRR at last follow-up was significantly greater for cystic than for predominantly cystic nodules (89.7% versus 78.2%, P < 0.001). Therapeutic success rates were 96.1% in cystic and 82.2% in predominantly cystic nodules (P = 0.001). Additional treatment was required for 6 cystic (4.7%) and 23 predominantly cystic nodules (25.6%; P < 0.001)

Bivariate correlation analysis showed that initial volume (r = −0.216, P = 0.001), proportion of solid component (r = −0.373, P < 0.001), vascularity (r = -0.308, P < 0.001), and number of sessions (r = −0.144, P = 0.034) were each significantly associated with VRR at last follow-up. Multiple linear regression analysis showed that initial volume (P = 0.007), proportion of solid component (P < 0.001), and vascularity (P < 0.001) were independent predictors of VRR at last follow-up, whereas the number of sessions was not (Table 2).
Table 2

Multivariate analysis of factors independently related to the efficacy of ethanol ablation in total thyroid nodules

Variables

Total thyroid nodules

β ± SE

P value

Initial volume

−5.952 ± 2.172

0.007

Proportion of solid component

−9.206 ± 2.364

<0.001

Vascularity

−7.006 ± 1.938

<0.001

Internal fluid nature

−1.386 ± 2.786

0.619

Retention time

−0.894 ± 0.519

0.087

Number of sessions

−4.302 ± 3.742

0.252

SE standard error

Bivariate correlation showed that the initial volume (r = −0.278, P = 0.008) and vascularity (r = −0.290, P = 0.006) of predominantly cystic nodules were significantly associated with VRR, and that both remained independent predictors of VRR on multiple linear regression analysis (P = 0.011 and P = 0.001, respectively). Conversely, no factor was significantly associated with VRR of cystic nodules, both on bivariate correlation and multiple linear regression analysis (Table 3).
Table 3

Multivariate analysis of factors independently related to the efficacy of ethanol ablation in subgroups

Variables

Predominatly cystic nodules

Cystic nodules

β ± SE

P value

β ± SE

P value

Initial volume

−10.384 ± 3.969

0.011

−1.734 ± 2.397

0.471

Vascularity

−11.608 ± 3.482

0.001

−3.262 ± 2.182

0.138

Internal fluid nature

3.543 ± 5.082

0.488

−3.333 ± 3.104

0.285

Retention time

−0.922 ± 0.927

0.323

−0.523 ± 0.592

0.379

Number of sessions

−8.617 ± 5.312

0.109

−0.483 ± 6.562

0.941

When we assessed the effects of ethanol retention time, we found that nodules that retained ethanol for 10 min were significantly greater in size than nodules that retained ethanol for 2 and 5 min (P = 0.05). However, mean VRR at last follow-up did not differ significantly among the three groups (P = 0.382; Table 4).
Table 4

Comparison of the efficacy according to the ethanol retention time

Retention time

2 min (n = 41)

5 min (n = 69)

10 min (n = 107)

P value

Initial volume (ml)

19.0 ± 19.1

18.2 ± 17.0

12.5 ± 17.9

0.050

Last volume (ml)

3.3 ± 4.0

3.5 ± 7.2

2.5 ± 9.4

0.728

Volume reduction (%)

83.2 ± 13.4

83.5 ± 19.3

86.5 ± 15.5

0.382

Values are mean ± SD

There were no complications during the procedure and follow-up periods, except for five patients who complained of grade 1 pain during and immediately after the procedure, but their pain was relieved within several minutes. There were no major complications after EA, such as voice change, infection, Horner’s syndrome, or permanent hyperthyroidism or hypothyroidism.

Discussion

We have shown here that, although EA is effective and safe for both cystic and predominantly cystic nodules, it was more effective for cystic nodules than predominantly cystic nodules in terms of volume reduction, therapeutic success and additional treatment. Initial nodule volume and vascularity were independently associated with the efficacy of EA in predominantly cystic nodules, whereas no factors were related to EA efficacy in cystic nodules. We also found that an ethanol retention time of 2 min was sufficient.

Previous studies have reported that the efficacy of EA was 85–98.5% in cystic nodules [8, 9, 10, 27, 28], 64–73.2% in predominantly cystic nodules [6, 7, 29], and 38–47% in solid nodules [7, 30, 31, 32], with a recent study showing that EA was less effective in nodules with >20% solid component [13]. Using a large series of 217 thyroid nodules in 209 patients, we also found that the percentage of solid component was an independent predictor of EA efficacy. We therefore divided these thyroid nodules into two groups, cystic and predominantly cystic, according to the proportion of solid component, and analysed factors associated with EA efficacy in each group separately.

We found that EA was significantly less effective for predominantly cystic nodules of an initial volume >10 ml and vascularity grades 1–3. Studies of the relationship between initial nodule volume and EA efficacy have yielded conflicting results, showing a negative correlation [6], no correlation or a positive correlation [2, 29]. As the percentage of solid component may increase in proportion to initial nodule volume, the efficacy of EA may be influenced by the initial volume of predominantly cystic nodules. In addition, drainage of ethanol during EA may be enhanced by internal vascularity, thus limiting the efficacy of EA [7].

We failed to identify any factors related to the efficacy of EA in cystic nodules, suggesting that EA is almost always effective in the treatment of cystic nodules, regardless of treatment or pre-treatment factors. These findings provide further evidence of the use of EA as a first-line treatment technique for cystic thyroid nodules [13, 14].

In most previous studies, injected ethanol was not removed, although other studies utilised ethanol retention times of 2 min [1, 32], 5 min [8] or 10 min [21, 22]. To our knowledge, our study is the first to show that EA efficacy is independent of ethanol retention time, indicating that retention for 2 min is sufficient. Ethanol reacts rapidly with cells, inducing cell death by lysing the cell membrane and denaturing proteins, resulting in vascular occlusion [27]. As longer ethanol retention times may increase patient inconvenience and complications, a shorter retention time may be sufficient.

Only five of our 209 patients (2.4%) experienced mild local pain at the injection site, with all experiencing relief of pain after several minutes without medication. We found that injecting and aspirating the ethanol by one needle puncture through a trans-isthmic approach minimised complications. The trans-isthmic approach, by which the needle approaches from the medial (isthmus) to the lateral aspect of a targeted nodule, allows the needle to pass through sufficient thyroid parenchyma to prevent a change in the position of the needle tip during swallowing or talking, as well as preventing ethanol leakage outside the thyroid gland. This approach has been used for EA as well as for RF ablation of thyroid nodules [13, 14, 18, 20, 21, 22, 24].

In conclusion, we found that EA was effective for both cystic and predominantly cystic nodules, especially for the former. Although the effectiveness of EA was reduced in large (initial volume >10 ml) or vascular predominantly cystic nodules, it was effective in cystic nodules regardless of treatment or pretreatment factors.

References

  1. 1.
    Bennedbaek FN, Hegedus L (2003) Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab 88:5773–5777PubMedCrossRefGoogle Scholar
  2. 2.
    Del Prete S, Caraglia M, Russo D et al (2002) Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid 12:815–821PubMedCrossRefGoogle Scholar
  3. 3.
    Mazzaferri EL (1999) An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421–427PubMedCrossRefGoogle Scholar
  4. 4.
    Sarda AK, Bal S, Dutta Gupta S, Kapur MM (1988) Diagnosis and treatment of cystic disease of the thyroid by aspiration. Surgery 103:593–596PubMedGoogle Scholar
  5. 5.
    Smith MD, Serpell JW, Morgan JL, Cheng MS (2003) Fine needle aspiration in the management of benign thyroid cysts. ANZ J Surg 73:477–479PubMedCrossRefGoogle Scholar
  6. 6.
    Cho YS, Lee HK, Ahn IM et al (2000) Sonographically guided ethanol sclerotherapy for benign thyroid cysts: results in 22 patients. AJR Am J Roentgenol 174:213–216PubMedGoogle Scholar
  7. 7.
    Kim JH, Lee HK, Lee JH, Ahn IM, Choi CG (2003) Efficacy of sonographically guided percutaneous ethanol injection for treatment of thyroid cysts versus solid thyroid nodules. AJR Am J Roentgenol 180:1723–1726PubMedGoogle Scholar
  8. 8.
    Monzani F, Lippi F, Goletti O et al (1994) Percutaneous aspiration and ethanol sclerotherapy for thyroid cysts. J Clin Endocrinol Metab 78:800–802PubMedCrossRefGoogle Scholar
  9. 9.
    Zingrillo M, Torlontano M, Chiarella R et al (1999) Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid 9:763–767PubMedCrossRefGoogle Scholar
  10. 10.
    Zingrillo M, Torlontano M, Ghiggi MR et al (1996) Percutaneous ethanol injection of large thyroid cystic nodules. Thyroid 6:403–408PubMedCrossRefGoogle Scholar
  11. 11.
    Kim DW, Rho MH, Kim HJ, Kwon JS, Sung YS, Lee SW (2005) Percutaneous ethanol injection for benign cystic thyroid nodules: is aspiration of ethanol-mixed fluid advantageous? AJNR Am J Neuroradiol 26:2122–2127PubMedGoogle Scholar
  12. 12.
    Yasuda K, Ozaki O, Sugino K et al (1992) Treatment of cystic lesions of the thyroid by ethanol instillation. World J Surg 16:958–961PubMedCrossRefGoogle Scholar
  13. 13.
    Jang SW, Baek JH, Kim JK et al (2011) How to manage the patients with unsatisfactory results after ethanol ablation for thyroid nodules: role of radiofrequency ablation. Eur J Radiol. doi:10.1016/j.ejrad.2011.02.039
  14. 14.
    Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH (2010) Radiofrequency ablation (RFA) of benign thyroid nodules in patients with incompletely resolved clinical problems after ethanol ablation (EA). World J Surg 34:1488–1493PubMedCrossRefGoogle Scholar
  15. 15.
    Moon WJ, Baek JH, Jung SL et al (2011) Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 12:1–14PubMedCrossRefGoogle Scholar
  16. 16.
    Moon WJ, Jung SL, Lee JH et al (2008) Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study. Radiology 247:762–770PubMedCrossRefGoogle Scholar
  17. 17.
    Ha EJ, Baek JH, Lee JH (2011) The efficacy and complications of radiofrequency ablation of thyroid nodules. Curr Opin Endocrinol Diabetes Obes 18:310–314PubMedGoogle Scholar
  18. 18.
    Jeong WK, Baek JH, Rhim H et al (2008) Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol 18:1244–1250PubMedCrossRefGoogle Scholar
  19. 19.
    Baek JH, Kim YS, Sung JY, Choi H, Lee JH (2011) Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 197:W331–W336PubMedCrossRefGoogle Scholar
  20. 20.
    Kim SM, Baek JH, Kim YS et al (2010) Efficacy and safety of ethanol ablation for thyroglossal duct cysts. AJNR Am J Neuroradiol 32:306–309PubMedCrossRefGoogle Scholar
  21. 21.
    Sung JY, Baek JH, Kim YS et al (2008) One-step ethanol ablation of viscous cystic thyroid nodules. AJR Am J Roentgenol 191:1730–1733PubMedCrossRefGoogle Scholar
  22. 22.
    Sung JY, Kim YS, Choi H, Lee JH, Baek JH (2011) Optimum first-line treatment technique for benign cystic thyroid nodules: ethanol ablation or radiofrequency ablation? AJR Am J Roentgenol 196:W210–W214PubMedCrossRefGoogle Scholar
  23. 23.
    Baek JH, Lee JH, Valcavi R, Pacella CM, Rhim H, Na DG (2011) Thermal ablation for benign thyroid nodules: radiofrequency and laser. Korean J Radiol 12:525–540PubMedCrossRefGoogle Scholar
  24. 24.
    Baek JH, Kim YS, Lee D, Huh JY, Lee JH (2010) Benign predominantly solid thyroid nodules: prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. AJR Am J Roentgenol 194:1137–1142PubMedCrossRefGoogle Scholar
  25. 25.
    Baek JH, Moon WJ, Kim YS, Lee JH, Lee D (2009) Radiofrequency ablation for the treatment of autonomously functioning thyroid nodules. World J Surg 33:1971–1977PubMedCrossRefGoogle Scholar
  26. 26.
    Park NH, Kim DW, Park HJ et al (2011) Thyroid cysts treated with ethanol ablation can mimic malignancy during sonographic follow-up. J Clin Ultrasound 39:441–446PubMedCrossRefGoogle Scholar
  27. 27.
    Valcavi R, Frasoldati A (2004) Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. Endocr Pract 10:269–275PubMedGoogle Scholar
  28. 28.
    Zingrillo M, Ghiggi MR, Liuzzi A (1996) A large, nonfunctioning parathyroid cyst recurring after aspiration and subsequently cured by percutaneous ethanol injection. J Clin Ultrasound 24:378–382PubMedCrossRefGoogle Scholar
  29. 29.
    Lee SJ, Ahn IM (2005) Effectiveness of percutaneous ethanol injection therapy in benign nodular and cystic thyroid diseases: long-term follow-up experience. Endocr J 52:455–462PubMedCrossRefGoogle Scholar
  30. 30.
    Bennedbaek FN, Nielsen LK, Hegedus L (1998) Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: a randomized trial. J Clin Endocrinol Metab 83:830–835PubMedCrossRefGoogle Scholar
  31. 31.
    Caraccio N, Goletti O, Lippolis PV (1997) Is percutaneous ethanol injection a useful alternative for the treatment of the cold benign thyroid nodule? Five years’ experience. Thyroid 7:699–704PubMedCrossRefGoogle Scholar
  32. 32.
    Bennedbaek FN, Karstrup S, Hegedus L (1997) Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur J Endocrinol 136:240–250PubMedCrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2012

Authors and Affiliations

  • Young Joong Kim
    • 1
  • Jung Hwan Baek
    • 1
  • Eun Ju Ha
    • 1
  • Hyun Kyung Lim
    • 1
  • Jeong Hyun Lee
    • 1
  • Jin Young Sung
    • 3
  • Jae Kyun Kim
    • 4
  • Tae Yong Kim
    • 2
  • Won Bae Kim
    • 2
  • Young Kee Shong
    • 2
  1. 1.Department of Radiology and Research Institute of RadiologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulSouth Korea
  2. 2.Department of Endocrinology and MetabolismUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulSouth Korea
  3. 3.Department of Radiology, Thyroid CenterDaerim St. Mary’s HospitalSeoulSouth Korea
  4. 4.Department of RadiologyChung-Ang University College of MedicineSeoulSouth Korea

Personalised recommendations